The dopamine and cAMP regulated phosphoprotein, 32kDa (DARPP-32) signaling pathway: A novel therapeutic target in traumatic brain injury

Experimental Neurology

Volumn 229, Issue 2, 2011, Pages 300-307

  Bales, James W ^a,b   Yan, Hong Q ^a,b   Ma, Xiecheng ^a,b   Li, Youming ^a,b   Samarasinghe, Ranmal ^b   Dixon, C Edward ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Amantadine; DARPP 32; Dopamine; Striatum; TBI

Indexed keywords

AMANTADINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHOSPHOPROTEIN DARPP 32; PHOSPHOPROTEIN PHOSPHATASE 1; THREONINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC ACTIVITY; DRUG MECHANISM; ENZYME ACTIVITY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; TRAUMATIC BRAIN INJURY;

AMANTADINE; ANIMALS; BLOTTING, WESTERN; BRAIN INJURIES; CORPUS STRIATUM; DOPAMINE AGENTS; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOHISTOCHEMISTRY; MALE; NEURONS; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION;

EID: 79956142512     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2011.02.013     Document Type: Article

References (60)

1. Ahn J.H., Sung J.Y., McAvoy T., Nishi A., Janssens V., Goris J., Greengard P., Nairn A.C. The B'/PR72 subunit mediates Ca2+-dependent dephosphorylation of DARPP-32 by protein phosphatase 2A. Proc. Natl Acad. Sci. USA 2007, 104:9876-9881.
2. Andreassen P.R., Lacroix F.B., Villa-Moruzzi E., Margolis R.L. Differential subcellular localization of protein phosphatase-1 alpha, gamma1, and delta isoforms during both interphase and mitosis in mammalian cells. J. Cell Biol. 1998, 141:1207-1215.
3. Baldo B.A., Kelley A.E. Discrete neurochemical coding of distinguishable motivational processes: insights from nucleus accumbens control of feeding. Psychopharmacology (Berl.) 2007, 191:439-459.
4. Bales J.W., Wagner A.K., Kline A.E., Dixon C.E. Persistent cognitive dysfunction after traumatic brain injury: a dopamine hypothesis. Neurosci. Biobehav. Rev. 2009, 33:981-1003.
5. Bateup H.S., Svenningsson P., Kuroiwa M., Gong S., Nishi A., Heintz N., Greengard P. Cell type-specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs. Nat. Neurosci. 2008, 11:932-939.
6. Bertran-Gonzalez J., Bosch C., Maroteaux M., Matamales M., Herve D., Valjent E., Girault J.A. Opposing patterns of signaling activation in dopamine D1 and D2 receptor-expressing striatal neurons in response to cocaine and haloperidol. J. Neurosci. 2008, 28:5671-5685.
7. Brenner M., Haass A., Jacobi P., Schimrigk K. Amantadine sulphate in treating Parkinson's disease: clinical effects, psychometric tests and serum concentrations. J. Neurol. 1989, 236:153-156.
8. Calabresi P., Picconi B., Tozzi A., Di Filippo M. Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends Neurosci. 2007, 30:211-219.
9. Centonze D., Picconi B., Gubellini P., Bernardi G., Calabresi P. Dopaminergic control of synaptic plasticity in the dorsal striatum. Eur. J. Neurosci. 2001, 13:1071-1077.
10. Choe E.S., Parelkar N.K., Kim J.Y., Cho H.W., Kang H.S., Mao L., Wang J.Q. The protein phosphatase 1/2A inhibitor okadaic acid increases CREB and Elk-1 phosphorylation and c-fos expression in the rat striatum in vivo. J. Neurochem. 2004, 89:383-390.
11. Coccurello R., Breysse N., Amalric M. Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats. Neuropsychopharmacology 2004, 29:1451-1461.
12. da Cruz e Silva E.F., Fox C.A., Ouimet C.C., Gustafson E., Watson S.J., Greengard P. Differential expression of protein phosphatase 1 isoforms in mammalian brain. J. Neurosci. 1995, 15:3375-3389.
13. DeKosky S.T., Kochanek P.M., Clark R.S., Ciallella J.R., Dixon C.E. Secondary injury after head trauma: subacute and long-term mechanisms. Semin. Clin. Neuropsychiatry 1998, 3:176-185.
14. Dixon C.E., Clifton G.L., Lighthall J.W., Yaghmai A.A., Hayes R.L. A controlled cortical impact model of traumatic brain injury in the rat. J. Neurosci. Methods 1991, 39:253-262.
15. Dixon C.E., Kraus M.F., Kline A.E., Ma X., Yan H.Q., Griffith R.G., Wolfson B.M., Marion D.W. Amantadine improves water maze performance without affecting motor behavior following traumatic brain injury in rats. Restor. Neurol. Neurosci. 1999, 14:285-294.
16. Donnemiller E., Brenneis C., Wissel J., Scherfler C., Poewe W., Riccabona G., Wenning G.K. Impaired dopaminergic neurotransmission in patients with traumatic brain injury: a SPECT study using 123I-beta-CIT and 123I-IBZM. Eur. J. Nucl. Med. 2000, 27:1410-1414.
17. Dunn-Meynell A., Pan S., Levin B.E. Focal traumatic brain injury causes widespread reductions in rat brain norepinephrine turnover from 6 to 24h. Brain Res. 1994, 660:88-95.
18. Fernandez E., Schiappa R., Girault J.A., Le Novere N. DARPP-32 is a robust integrator of dopamine and glutamate signals. PLoS Comput. Biol. 2006, 2:1619-1633.
19. Fienberg A.A., et al. DARPP-32: regulator of the efficacy of dopaminergic neurotransmission. Science 1998, 281:838-842.
20. Fineman I., Hovda D.A., Smith M., Yoshino A., Becker D.P. Concussive brain injury is associated with a prolonged accumulation of calcium: a 45Ca autoradiographic study. Brain Res. 1993, 624:94-102.
21. Genoux D., Haditsch U., Knobloch M., Michalon A., Storm D., Mansuy I.M. Protein phosphatase 1 is a molecular constraint on learning and memory. Nature 2002, 418:970-975.
22. Greenamyre J.T., O'Brien C.F. N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease. Arch. Neurol. 1991, 48:977-981.
23. Greengard P., Allen P.B., Nairn A.C. Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron 1999, 23:435-447.
24. Hakansson K., Lindskog M., Pozzi L., Usiello A., Fisone G. DARPP-32 and modulation of cAMP signaling: involvement in motor control and levodopa-induced dyskinesia. Parkinsonism Relat. Disord. 2004, 10:281-286.
25. Halpain S., Girault J.A., Greengard P. Activation of NMDA receptors induces dephosphorylation of DARPP-32 in rat striatal slices. Nature 1990, 343:369-372.
26. Hamada M., Hendrick J.P., Ryan G.R., Kuroiwa M., Higashi H., Tanaka M., Nairn A.C., Greengard P., Nishi A. Nicotine regulates DARPP-32 (dopamine- and cAMP-regulated phosphoprotein of 32kDa) phosphorylation at multiple sites in neostriatal neurons. J. Pharmacol. Exp. Ther. 2005, 315:872-878.
27. Hemmings H.C., Greengard P. DARPP-32, a dopamine-regulated phosphoprotein. Prog. Brain Res. 1986, 69:149-159.
28. Hemmings H.C., Nairn A.C., Elliott J.I., Greengard P. Synthetic peptide analogs of DARPP-32 (Mr 32,000 dopamine- and cAMP-regulated phosphoprotein), an inhibitor of protein phosphatase-1. Phosphorylation, dephosphorylation, and inhibitory activity. J. Biol. Chem. 1990, 265:20369-20376.
29. Hovda D.A., Yoshino A., Kawamata T., Katayama Y., Fineman I., Becker D.P. The increase in local cerebral glucose utilization following fluid percussion brain injury is prevented with kynurenic acid and is associated with an increase in calcium. Acta Neurochir. Suppl. (Wien) 1990, 51:331-333.
30. Huger F., Patrick G. Effect of concussive head injury on central catecholamine levels and synthesis rates in rat brain regions. J. Neurochem. 1979, 33:89-95.
31. Kline A.E., Yan H.Q., Bao J., Marion D.W., Dixon C.E. Chronic methylphenidate treatment enhances water maze performance following traumatic brain injury in rats. Neurosci. Lett. 2000, 280:163-166.
32. Kline A.E., Massucci J.L., Ma X., Zafonte R.D., Dixon C.E. Bromocriptine reduces lipid peroxidation and enhances spatial learning and hippocampal neuron survival in a rodent model of focal brain trauma. J. Neurotrauma 2004, 21:1712-1722.
33. Kobori N., Clifton G.L., Dash P.K. Enhanced catecholamine synthesis in the prefrontal cortex after traumatic brain injury: implications for prefrontal dysfunction. J. Neurotrauma 2006, 23:1094-1102.
34. Koch K., Wagner G., Nenadic I., Schachtzabel C., Schultz C., Roebel M., Reichenbach J.R., Sauer H., Schlösser R.G. Fronto-striatal hypoactivation during correct information retrieval in patients with schizophrenia: an fMRI study. Neuroscience 2008, 153(1):54-62. 22.
35. Kochanek P.M. Ischemic and traumatic brain injury: pathobiology and cellular mechanisms. Crit. Care Med. 1993, 21:S333-S335.
36. Kopnisky K.L., Chalecka-Franaszek E., Gonzalez-Zulueta M., Chuang D.M. Chronic lithium treatment antagonizes glutamate-induced decrease of phosphorylated CREB in neurons via reducing protein phosphatase 1 and increasing MEK activities. Neuroscience 2003, 116:425-435.
37. Kraus M.F., Smith G.S., Butters M., Donnell A.J., Dixon E., Yilong C., Marion D. Effects of the dopaminergic agent and NMDA receptor antagonist amantadine on cognitive function, cerebral glucose metabolism and D2 receptor availability in chronic traumatic brain injury: a study using positron emission tomography (PET). Brain Inj. 2005, 19:471-479.
38. Lang U.E., Puls I., Muller D.J., Strutz-Seebohm N., Gallinat J. Molecular mechanisms of schizophrenia. Cell. Physiol. Biochem. 2007, 20(6):687-702.
39. Massucci J.L., Kline A.E., Ma X., Zafonte R.D., Dixon C.E. Time dependent alterations in dopamine tissue levels and metabolism after experimental traumatic brain injury in rats. Neurosci. Lett. 2004, 372:127-131.
40. McAllister T.W., Flashman L.A., Sparling M.B., Saykin A.J. Working memory deficits after traumatic brain injury: catecholaminergic mechanisms and prospects for treatment - a review. Brain Inj. 2004, 18:331-350.
41. McIntosh T.K., Yu T., Gennarelli T.A. Alterations in regional brain catecholamine concentrations after experimental brain injury in the rat. J. Neurochem. 1994, 63:1426-1433.
42. Merims D., Freedman M. Cognitive and behavioural impairment in Parkinson's disease. Int. Rev. Psychiatry 2008, 20(4):364-373.
43. Nairn A.C., Svenningsson P., Nishi A., Fisone G., Girault J.A., Greengard P. The role of DARPP-32 in the actions of drugs of abuse. Neuropharmacology 2004, 47(Suppl 1):14-23.
44. Nishi A., Bibb J.A., Matsuyama S., Hamada M., Higashi H., Nairn A.C., Greengard P. Regulation of DARPP-32 dephosphorylation at PKA- and Cdk5-sites by NMDA and AMPA receptors: distinct roles of calcineurin and protein phosphatase-2A. J. Neurochem. 2002, 81:832-841.
45. Osteen C.L., Giza C.C., Hovda D.A. Injury-induced alterations in N-methyl-D-aspartate receptor subunit composition contribute to prolonged 45calcium accumulation following lateral fluid percussion. Neuroscience 2004, 128:305-322.
46. Palmer A.M., Marion D.W., Botscheller M.L., Swedlow P.E., Styren S.D., DeKosky S.T. Traumatic brain injury-induced excitotoxicity assessed in a controlled cortical impact model. J. Neurochem. 1993, 61:2015-2024.
47. Peinemann A., Schuller S., Pohl C., Jahn T., Weindl A., Kassubek J. Executive dysfunction in early stages of Huntington's disease is associated with striatal and insular atrophy: a neuropsychological and voxel-based morphometric study. J. Neurol. Sci. 2005, 239(1):11-19. 15.
48. Pennartz C.M., Kitai S.T. Hippocampal inputs to identified neurons in an in vitro slice preparation of the rat nucleus accumbens: evidence for feed-forward inhibition. J. Neurosci. 1991, 11:2838-2847.
49. Ridley R.M., Cummings R.M., Leow-Dyke A., Baker H.F. Neglect of memory after dopaminergic lesions in monkeys. Behav. Brain Res. 2006, 166:253-262.
50. Sawamoto N., Honda M., Hanakawa T., Aso T., Inoue M., Toyoda H., Ishizu K., Fukuyama H., Shibasaki H. Cognitive slowing in Parkinson disease is accompanied by hypofunctioning of the striatum. Neurology 2007, 68:1062-1068.
51. Shapira Y., Yadid G., Cotev S., Shohami E. Accumulation of calcium in the brain following head trauma. Neurol. Res. 1989, 11:169-172.
52. Shima H., Hatano Y., Chun Y.S., Sugimura T., Zhang Z., Lee E.Y., Nagao M. Identification of PP1 catalytic subunit isotypes PP1 gamma 1, PP1 delta and PP1 alpha in various rat tissues. Biochem. Biophys. Res. Commun. 1993, 192:1289-1296.
53. Svenningsson P., Nishi A., Fisone G., Girault J.A., Nairn A.C., Greengard P. DARPP-32: an integrator of neurotransmission. Annu. Rev. Pharmacol. Toxicol. 2004, 44:269-296.
54. Valjent E., Pascoli V., Svenningsson P., Paul S., Enslen H., Corvol J.C., Stipanovich A., Caboche J., Lombroso P.J., Nairn A.C., Greengard P., Herve D., Girault J.A. Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. Proc. Natl Acad. Sci. USA 2005, 102:491-496.
55. Vertes R.P. Interactions among the medial prefrontal cortex, hippocampus and midline thalamus in emotional and cognitive processing in the rat. Neuroscience 2006, 142:1-20.
56. Wagner A.K., Chen X., Kline A.E., Li Y., Zafonte R.D., Dixon C.E. Gender and environmental enrichment impact dopamine transporter expression after experimental traumatic brain injury. Exp. Neurol. 2005, 195:475-483.
57. Wagner A.K., Drewencki L.L., Chen X., Santos F.R., Khan A.S., Harun R., Torres G.E., Michael A.C., Dixon C.E. Chronic methylphenidate treatment enhances striatal dopamine neurotransmission after experimental traumatic brain injury. J. Neurochem. 2009, 108:986-997.
58. Warden D.L., Gordon B., McAllister T.W., Silver J.M., Barth J.T., Bruns J., Drake A., Gentry T., Jagoda A., Katz D.I., Kraus J., Labbate L.A., Ryan L.M., Sparling M.B., Walters B., Whyte J., Zapata A., Zitnay G. Guidelines for the pharmacologic treatment of neurobehavioral sequelae of traumatic brain injury. J. Neurotrauma 2006, 23:1468-1501.
59. Yan H.Q., Yu J., Kline A.E., Letart P., Jenkins L.W., Marion D.W., Dixon C.E. Evaluation of combined fibroblast growth factor-2 and moderate hypothermia therapy in traumatically brain injured rats. Brain Res. 2000, 887:134-143.
60. Yan H.Q., Ma X., Chen X., Li Y., Shao L., Dixon C.E. Delayed increase of tyrosine hydroxylase expression in rat nigrostriatal system after traumatic brain injury. Brain Res. 2007, 1134:171-179.